153 related articles for article (PubMed ID: 35420780)
1. Targeted Intervention of NF2-YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC.
Hou L; Pu L; Chen Y; Bai Y; Zhou Y; Chen M; Wang S; Lv Y; Ma C; Cheng P; Zhang K; Liang Q; Deng S; Wang D
ACS Nano; 2022 Apr; 16(4):5807-5819. PubMed ID: 35420780
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
3. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
[TBL] [Abstract][Full Text] [Related]
4. Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
Chan SH; Tsai KW; Chiu SY; Kuo WH; Chen HY; Jiang SS; Chang KJ; Hung WC; Wang LH
Mol Cancer Ther; 2019 Jan; 18(1):147-161. PubMed ID: 30381446
[TBL] [Abstract][Full Text] [Related]
5. The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis.
Zhou X; Yan Z; Hou J; Zhang L; Chen Z; Gao C; Ahmad NH; Guo M; Wang W; Han T; Chang T; Kang X; Wang L; Liang Y; Li X
Oncogene; 2024 Feb; 43(7):495-510. PubMed ID: 38168654
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
[TBL] [Abstract][Full Text] [Related]
7. Association of human breast cancer CD44
Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
Elife; 2021 Jul; 10():. PubMed ID: 34318746
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance.
Yang J; Jia Z; Zhang J; Pan X; Wei Y; Ma S; Yang N; Liu Z; Shen Q
Adv Healthc Mater; 2022 Jul; 11(13):e2102799. PubMed ID: 35395704
[TBL] [Abstract][Full Text] [Related]
9. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer.
Murthy D; Dutta D; Attri KS; Samanta T; Yang S; Jung KH; Latario SG; Putluri V; Huang S; Putluri N; Park JH; Kaipparettu BA
Cancer Lett; 2024 Apr; 587():216724. PubMed ID: 38373689
[TBL] [Abstract][Full Text] [Related]
10. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.
Yang P; Yu F; Yao Z; Ding X; Xu H; Zhang J
Cancer Immunol Immunother; 2023 Oct; 72(10):3191-3202. PubMed ID: 37418008
[TBL] [Abstract][Full Text] [Related]
11. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
13. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling.
Wu J; Minikes AM; Gao M; Bian H; Li Y; Stockwell BR; Chen ZN; Jiang X
Nature; 2019 Aug; 572(7769):402-406. PubMed ID: 31341276
[TBL] [Abstract][Full Text] [Related]
14. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
[TBL] [Abstract][Full Text] [Related]
16. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
17. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.
Deng X; Apple S; Zhao H; Song J; Lee M; Luo W; Wu X; Chung D; Pietras RJ; Chang HR
Oncotarget; 2017 Jun; 8(24):38294-38308. PubMed ID: 28418843
[TBL] [Abstract][Full Text] [Related]
18. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
Du J; Wang L; Huang X; Zhang N; Long Z; Yang Y; Zhong F; Zheng B; Lan W; Lin W; Ma W
Phytomedicine; 2021 May; 85():153551. PubMed ID: 33827043
[TBL] [Abstract][Full Text] [Related]
19. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk.
Li H; Yang P; Wang J; Zhang J; Ma Q; Jiang Y; Wu Y; Han T; Xiang D
J Hematol Oncol; 2022 Jan; 15(1):2. PubMed ID: 34991659
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin induced ferroptosis for triple-negative breast cancer therapy.
Yao X; Xie R; Cao Y; Tang J; Men Y; Peng H; Yang W
J Nanobiotechnology; 2021 Oct; 19(1):311. PubMed ID: 34627266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
